BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 18448548)

  • 1. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
    Viale G
    Breast; 2009 Oct; 18 Suppl 3():S32-6. PubMed ID: 19914539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.
    Dowsett M; Dunbier AK
    Clin Cancer Res; 2008 Dec; 14(24):8019-26. PubMed ID: 19088018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management.
    Malinowski DP
    Expert Rev Mol Diagn; 2007 May; 7(3):269-80. PubMed ID: 17489734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in projecting clustering results across gene expression-profiling datasets.
    Lusa L; McShane LM; Reid JF; De Cecco L; Ambrogi F; Biganzoli E; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2007 Nov; 99(22):1715-23. PubMed ID: 18000217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New generation of molecular prognostic and predictive tests for breast cancer.
    Pusztai L; Cristofanilli M; Paik S
    Semin Oncol; 2007 Apr; 34(2 Suppl 3):S10-6. PubMed ID: 17512431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic applications of gene expression signatures in breast cancer.
    Normanno N; De Luca A; Carotenuto P; Lamura L; Oliva I; D'Alessio A
    Oncology; 2009; 77 Suppl 1():2-8. PubMed ID: 20130425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting features of breast cancer with gene expression patterns.
    Lu X; Lu X; Wang ZC; Iglehart JD; Zhang X; Richardson AL
    Breast Cancer Res Treat; 2008 Mar; 108(2):191-201. PubMed ID: 18297396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular assays to predict prognosis of breast cancer.
    Paik S
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):681-2. PubMed ID: 17982408
    [No Abstract]   [Full Text] [Related]  

  • 16. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy.
    Barrett-Lee PJ
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S125-33. PubMed ID: 16113089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.